Literature DB >> 10501481

Integrin alpha(v)beta3 (vitronectin receptor) is a candidate receptor for the virulent echovirus 9 strain Barty.

Birgit Nelsen-Salz1, Hans J Eggers1, Holger Zimmermann1.   

Abstract

The enterovirus echovirus 9 strain Barty (E9/Barty) is pathogenic for newborn mice as well as for humans. In contrast to the apathogenic prototype strain Hill, strain Barty encodes an RGD motif in the C-terminal part of the structural protein VP1. Data are presented that show that E9/Barty binds its target cells via contact of the RGD motif to the alpha(v)beta3 integrin (vitronectin receptor), whereas prototype Hill uses a different, still unidentified receptor site. Furthermore, virus titres of murine muscle tissue were compared after infection of newborn and 1-, 2-, 3- and 12-week-old mice. The replication capacity of the virus decreased dramatically with age of the infected mice. Since E9/Barty does not replicate or replicates only poorly in mice older than about 5 days, and expression of the vitronectin receptor is reported to be down-regulated in striated muscle tissue during development, it is suggested that susceptibility of mice to this echovirus infection is controlled by the availability of alpha(v)beta3 integrin.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10501481     DOI: 10.1099/0022-1317-80-9-2311

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  24 in total

1.  Arginine-glycine-aspartic acid motif is critical for human parechovirus 1 entry.

Authors:  Y Boonyakiat; P J Hughes; F Ghazi; G Stanway
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

2.  Picornaviruses.

Authors:  Tobias J Tuthill; Elisabetta Groppelli; James M Hogle; David J Rowlands
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

3.  Gene mapping and phylogenetic analysis of the complete genome from 30 single-stranded RNA male-specific coliphages (family Leviviridae).

Authors:  Stephanie D Friedman; Fred J Genthner; Jennifer Gentry; Mark D Sobsey; Jan Vinjé
Journal:  J Virol       Date:  2009-08-26       Impact factor: 5.103

4.  High-efficiency utilization of the bovine integrin alpha(v)beta(3) as a receptor for foot-and-mouth disease virus is dependent on the bovine beta(3) subunit.

Authors:  S Neff; P W Mason; B Baxt
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

5.  Recovery of infectious foot-and-mouth disease virus from suckling mice after direct inoculation with in vitro-transcribed RNA.

Authors:  Eric Baranowski; Nicolás Molina; José Ignacio Núñez; Francisco Sobrino; Margarita Sáiz
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

6.  Interactions of foot-and-mouth disease virus with soluble bovine alphaVbeta3 and alphaVbeta6 integrins.

Authors:  Hernando Duque; Michael LaRocco; William T Golde; Barry Baxt
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

7.  Structural Basis of Human Parechovirus Neutralization by Human Monoclonal Antibodies.

Authors:  Shabih Shakeel; Brenda M Westerhuis; Ari Ora; Gerrit Koen; Arjen Q Bakker; Yvonne Claassen; Koen Wagner; Tim Beaumont; Katja C Wolthers; Sarah J Butcher
Journal:  J Virol       Date:  2015-07-08       Impact factor: 5.103

8.  Coxsackievirus A9 infects cells via nonacidic multivesicular bodies.

Authors:  Moona Huttunen; Matti Waris; Ritva Kajander; Timo Hyypiä; Varpu Marjomäki
Journal:  J Virol       Date:  2014-02-26       Impact factor: 5.103

Review 9.  Evolution of cell recognition by viruses: a source of biological novelty with medical implications.

Authors:  Eric Baranowski; Carmen M Ruiz-Jarabo; Nonia Pariente; Nuria Verdaguer; Esteban Domingo
Journal:  Adv Virus Res       Date:  2003       Impact factor: 9.937

10.  A rapid and efficient method for studies of virus interaction at the host cell surface using enteroviruses and real-time PCR.

Authors:  Nina Jonsson; Maria Gullberg; Stina Israelsson; A Michael Lindberg
Journal:  Virol J       Date:  2009-12-07       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.